These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://abelcpyd798342.mybjjblog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-51271087